St. Jude Children’s researchers better define hyperdiploidy in childhood B-ALL

SAN DIEGO — Treatment with the B-cell depleting agent obinutuzumab (Gazyva) helped patients with lupus nephritis avoid the most serious adverse outcomes, according to a

Kyver­na Ther­a­peu­tics, a clin­i­cal-stage biotech ex­am­in­ing CAR-T cell ther­a­py’s po­ten­tial to treat au­toim­mune dis­eases, has filed for an ini­tial pub­lic of­fer­ing. The Cal­i­for­nia biotech plans